Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies

Journal of the National Cancer Institute

Volumn 88, Issue 20, 1996, Pages 1442-1455

  Harris, Curtis C ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHLORMETHINE; CISPLATIN; ETOPOSIDE; GROWTH FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; MEMBRANE RECEPTOR; OKADAIC ACID; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN P53;

APOPTOSIS; CANCER; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DNA DAMAGE; EXPRESSION VECTOR; GENE MUTATION; GENE THERAPY; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; NONHUMAN; ONCOGENE; PROTEIN PHOSPHORYLATION; REVIEW; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA, NEOPLASM; GENE THERAPY; GENES, P53; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS; PHOSPHORYLATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029845760     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.20.1442     Document Type: Review

References (288)

1. Harris CC. p53 tumor suppressor gene. From the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. In press.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
4. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
5. Lane DP. A death in the life of p53 [news; see comment citations in Medline]. Nature 1993;362:786-7.
6. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994;5:221-7.
7. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 1994;84:2391-411.
8. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271: 1744-7.
9. Ko LJ., Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
10. Lane DP. Cancer. p53, guardian of the genome [news; see comment citations in Medline]. Nature 1992;358:15-6.
11. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996;93:2442-7.
12. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984;4:1689-94.
13. Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991;51:4279-86.
14. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
15. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995;10:2263-70.
16. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995; 55:1643-8.
17. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994;14:1815-23.
18. Scheffner M, Wemess BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
19. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75:765-78.
20. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-51.
21. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 1996;93:4827-32.
22. Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995; 81:1021-9.
23. Brain R, Jenkins JR. Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene 1994;9:1775-80.
24. Oberosler P, Hloch P, Ramsperger U, Stahl H. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 1993;12:2389-96.
25. Foord OS, Bhattacharya P, Reich Z, Rotter V. DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res 1991;19:5191-8.
26. Reed M, Woelker B, Wang P, Wang Y, Andersen ME, Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A 1995;92:9455-9.
27. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995;81:1013-20.
28. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.Cell 1993;75:805-16.
29. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases [see comment citation in Medline]. Nature 1993;366:701-4.
31. Smith ML, Chen IT, Zhan Q, Bae I. Chen CY, Gilmer TM, et al. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen [see comment citations in Medline]. Science 1994;266:1376-80.
32. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-7.
33. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994; 9:1791-8.
34. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
35. Miyashita T, Krajewski S, Krajewska M, Wang, HG, Lin HK, Lieberman DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
36. Selo E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, et al. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 1992;89:12028-32.
37. Liu X, Miller CW, Koeffler PH, Berk AJ. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 1993;13:3291-300.
38. Truant R, Xiao H, Ingles CJ, Greenblatt J. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem 1993;268:2284-7.
39. Chen X, Farmer G, Zhu H, Prywes R, Prives C. Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation [published erratum appears in Genes Dev 1993:7:2652]. Genes Dev 1993;7:1837-49.
40. Miller SD, Farmer G, Prives C. p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner. Mol Cell Biol 1995;15:6554-60.
41. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect of activated human p53 on nuclear DNA replication. EMBO J 1995;14:2099-105.
42. Dutta A, Ruppert JM, Aster JC, Winchester E. Inhibition of DNA replication factor RPA by p53 [see comment citation in Medline]. Nature 1993; 365:79-82.
43. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995;10:188-95.
44. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994;91:2230-4.
45. Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier JL, et al. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 1994;14:7013-24.
46. Leveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM. et al. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J 1996;15:1615-24.
47. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996;35: 5778-86.
48. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, et al. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996;10:1219-32.
49. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes [see comment citation in Medline]. Nature 1994;370:220-3.
50. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995; 9:2170-83.
51. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21Waf1/cip1. Genes Dev 1994;8:2817-30.
52. Del Sal G, Ruaro EM, Utrera R, Cole CN, Levine AJ, Schneider C. Gas1-induced growth suppression requires a transactivation-independent p53 function. Mol Cell Biol 1995;15:7152-60.
53. Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 1995;11:2411-8.
54. Harris C, Grady H, Svoboda D. Alterations in pancreatic and hepatic ultrastructure following acute cycloheximide intoxication. J Ultrastruct Res 1968;22:240-51.
55. Martin SJ. Protein or RNA synthesis inhibition induces apoptosis of mature human CD4+ T cell blasts. Immunol Lett 1993;35:125-34.
56. Bazar LS, Deeg HJ. Ultraviolet B-induced DNA fragmentation (apoptosis) in activated T-lymphocytes and Jurkat cells is augmented by inhibition of RNA and protein synthesis. Exp Hematol 1992;20:80-6.
57. Sekiguchi T, Nakashima T, Hayashida T, Kuraoka A, Hashimoto S, Tsuchida N, et al. Apoptosis is induced in BHK cells by the tsBN462/13 mutation in the CCG1/TAFJI250 subunit of the TFIID basal transcription factor. Exp Cell Res 1995;218:490-8.
58. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene. In press.
59. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-7.
60. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
61. Tomlinson IP, Bodmer WF. Failure of programmed cell death and differentiation as causes of tumors: some simple mathmatical models. Proc Natl Acad Sci U S A 1995;92:11130-4.
62. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comment citations in Medline]. Nature 1996; 379:88-91.
63. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-22.
64. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins [published erratum appears in Proc Natl Acad Sci U S A 1992;89:9974]. Proc Natl Acad Sci U S A 1992;89:7742-6.
65. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
66. White E. Tumour biology. p53, guardian of Rb [news; see comment citation in Medline]. Nature 1994;371:21-2.
67. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994;8:1285-99.
68. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens [see comment citation in Medline]. Nature 1994;371:72-4.
69. Pizzo PA, Horowitz ME, Poplack DG, Hays DM, Kun LE. Solid tumors of childhood. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1993; 1738-91.
70. Milner AE, Grand RJ, Waters CM, Gregory CD. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 1993;8:3385-91.
71. Carbone DP, Minna JA. The molecular genetics of lung cancer. Adv Intern Med 1992;37:153-71.
72. Greenblatt MS, Harris CC. Molecular genetics of lung cancer. Cancer Surv 1995;25:293-313.
73. Hunter T. Braking the cycle. Cell 1993;75:839-41.
74. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
75. Ullrich SJ, Anderson CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992;267: 15259-62.
76. Meek DW. Post-translational modification of p53. Semin Cancer Biol 1994;5:203-10.
77. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A 1990;87:4766-70.
78. Addison C, Jenkins JR, Sturzbecher HW. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 1990;5: 423-6.
79. Sturzbecher HW, Maimets T, Chumakov P, Brain R, Addison C, Simanis V, et al. p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene 1990;5:795-801.
80. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 1990;9:3253-60.
81. Lees-Miller SP, Chen YR, Anderson CW. Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol 1990;10:6472-81.
82. Milne DM, Palmer RH, Campbell DG, Meek DW. Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene 1992;7:1361-9.
83. Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci U S A 1992; 89:11627-31.
84. Milne DM, Campbell DG, Caudwell FB, Meek DW. Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J Biol Chem 1994;269:9253-60.
85. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995; 270:5511-8.
86. Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 1995;376:88-91.
87. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1995;4:865-75.
88. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
89. Delphin C, Baudier J. The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of Ras-transformed embryo fibroblasts growth arrest. J Biol Chem 1994;269:29579-87.
90. Fiscella M, Zambrano N, Ullrich SJ, Unger T, Lin D, Cho B, et al. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene 1994;9:3249-57.
91. Skouv J, Jensen PO, Forchhammer J, Larsen JK, Lund LR. Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth Differ 1994;5:329-40.
92. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
93. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review, Int J Cancer 1994; 57:1-9.
94. Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 1996;56:2130-6.
95. Jego N, Thomas G, Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene 1993;8:209-13.
96. Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 1991;86:425-41.
97. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70: 523-6.
98. Thut CJ, Chen JL, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995;267:100-4.
99. Lu H, Levine AJ. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A 1995;92:5154-8.
100. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249:1049-51.
101. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990;249:1046-9.
102. Martin DW, Munoz RM, Subler MA, Deb S. p53 binds to the TATA-binding protein-TATA complex. J Biol Chem 1993;268:13062-7.
103. Mack DH, Vartikar J, Pipas JM, Laimins LA. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 1993;363:281-3.
104. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994;8:1235-46.
105. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995;267:1498-502.
106. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR [see comment citation in Medline] [published erratum appears in Science 1995;267:1515]. Science 1994; 265:386-91.
107. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53 [published erratum appears in Nat Struct Biol 1995;2:81]. Nat Struc Biol 1994;1:877-90.
108. Bakalkin G, Yakovleva T, Selivanova G, Magnusson KP, Szekely L, Kisaleva E, et al. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A 1994;91:413-7.
109. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas [see comment citation in Medline]. Nature 1991;350:427-8.
110. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa [see comment citation in Medline]. Nature 1991;350:429-31.
111. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992;52:1635-8.
112. Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993;14:169-73.
113. Harris CC. The 1995 Walter Hubert Lecture-Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour suppressor gene. Br J Cancer 1996;73:261-9.
114. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264:1317-9.
115. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993;90:8586-90.
116. Ponchel F, Puisieux A, Tabone E, Michot JP, Froschl G, Morel AP, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res 1994;54:2064-8.
117. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, et al. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995;10:2103-11.
118. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991;252:842-4.
119. Shirakata Y, Kawada M, Fujiki Y, Sano H, Oda M, Yaginuma K, et al. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res 1989;80:617-21.
120. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990;343:457-61.
121. Twu JS, Schloemer RH. Transcriptional trans-activating function of hepatitis B virus. J Virol 1987;61:3448-53.
122. Spandau DF, Lee CH. Trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988;62:427-34.
123. Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A 1990;87:2970-4.
124. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A 1994;91:10350-4.
125. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:822-6.
126. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995;21:313-21.
127. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-17.
128. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-7.
129. Hino O, Nomura K, Ohtake K, Kawaguchi T, Sugano H, Kitagawa T. Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. Cancer Genet Cytogenet 1989;37:273-8.
130. Hino O, Tabata S, Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A 1991;88:9248-52.
131. Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 1991;11:12-9.
132. Wu L, Bayle JH, Elenbaas B, Pavletich NP, Levine AJ. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 1995;15:497-504.
133. Bakalkin G, Selivanova G, Yakovleva T, Kiseleva E, Kashuba E, Magnusson KP, et al. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res 1995;23:362-9.
134. Mayr GA, Reed M, Wang P, Wang Y, Schweds JF, Tegtmeyer P. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation. Cancer Res 1995;55:2410-7.
135. Hainaut P, Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 1993;53:4469-73.
136. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 1993; 21:3167-74.
137. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995;15:3892-903.
138. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comment citation in Medline]. Science 1994;265:346-55.
139. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene [see comment citations in Medline]. N Engl J Med 1993;329:1318-27.
140. Kinzler KW, Vogelstein B. Cancer therapy meets p53 [see comment citation in Medline]. N Engl J Med 1994;331:49-50.
141. Rowley JD, Aster JC, Sklar J. The clinical applications of new DNA diagnostic technology on the management of cancer patients. JAMA 1993;270:2331-7.
142. Sidransky D. Molecular markers in cancer: can we make better predictions? Int J Cancer 1995;64:1-2.
143. Cin PD, Trent JM. What should oncologists know about cytogenetics in solid tumors? Ann Oncol 1993;4:821-4.
144. Li FP, Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992; 84:1156-60.
145. Birrer MJ. Translational research and epithelial carcinogenesis: molecular diagnostic assays now - molecular screening assays soon? [editorial; comment]. J Natl Cancer Inst 1995;87:1041-3.
146. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-7.
147. Frebourg T, Barbier N, Kassel J, Ng YS, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 1992;52:6976-8.
148. Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol Cell Biol 1984;4:1402-10.
149. Eliyahu D, Michalovitz D, Oren M, Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 1985;316:158-60.
150. pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V. p53 increases experimental metastatic capacity of murine carcinoma cells. Mol Cell Biol 1988;8:2078-81.
151. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
152. Gerwin BI, Spillare E, Forrester K, Lehman TA, Kispert J, Welsh JA, et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor type beta 1. Proc Natl Acad Sci U S A 1992;89:2759-63.
153. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994;145:702-14.
154. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
155. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy [published erratum appears in Cancer 1994; 73:3108]. Cancer 1994;73:2013-26.
156. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 1995;6:3-16.
157. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 1995;6:53-60.
158. Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 1995;6:45-52.
159. Shimamura A, Fisher DE. p53 in life and death. Clin Cancer Res 1996; 2:435-40.
160. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
161. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes [see comment citation in Medline]. Nature 1993;362:847-9.
162. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bud CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways [see comment citation in Medline]. Nature 1993;362:849-52.
163. Lotem J, Sachs L. A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci U S A 1995;92:9672-6.
164. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
165. Bertrand R, Solary E, Jenkins J, Pommier Y. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 1993;207:388-97.
166. Bardeesy N, Falkoff D, Petruzzi MJ, Nowaik N, Zabel B, Adam M, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7:91-7.
167. Heimdal K, Lothe RA, Lystad S, Holm R, Fossa SD, Borresen AL. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosom Cancer 1993;6:92-7.
168. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993;82:3163-9.
169. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 1994;54:2077-9.
170. Goker E, Waltham M, Kheradpour A, Trippelt T, Mazumdar M, Elisseyeff Y, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995;86:677-84.
171. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesie M, Silber R, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-9.
172. Faraldi F, Calzolari A, Alfieri E, Mincione GP, Mincione F. Lack of detection of p53 expression in retinoblastoma tumor cells. Pathologica 1994;86:401-2.
173. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 1992;52:4273-6.
174. Gutierrez MI, Bhatia K, Diez B, Muriel FS, Epelman S, DeAndreas ML, et al. Prognostic significance of p53 mutations in small non-cleaved cell lymphomas. Int J Oncol 1994;4:567-71.
175. Elledge RM, Gray R, Mansour E, Yu Y, Clarke GM, Ravdin P, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87:1254-6.
176. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini M, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
177. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
178. Moreira LF, Naomoto Y, Hamada M, Kamikawa Y, Orita K. Assessment of apoptosis in oesopliageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res 1995;15:639-44.
179. Sauter ER, Ridge JA, Litwin S, Langer CJ. Pretreatmem p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Clin Cancer Res 1995;1:1407-12.
180. Righetti SC, Torre GD, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
181. Bracey TS, Miller JC, Preece A, Paraskeva C. Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10:2391-6.
182. Lin Y, Benchimol S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Mol Cell Biol 1995;15:6045-54.
183. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995;9: 600-11.
184. Gottlieb E, Haffner R, von Ruden T, Wagner EF, Oren M. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3-withdrawal. EMBO J 1994;13:1368-74.
185. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-31.
186. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994;64:127-54.
187. Gotlieb WH, Watson JM, Rezai A. Johnson M, Martinez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol 1994; 170:1121-30.
188. Ehinger M, Nilsson E, Persson AM, Olsson I, Gullberg U. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Differ 1995;6:9-17.
189. Wang L, Rayanade RJ, Garcia D, Patel K, Pan H, Sehgal PB. Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species. J Biol Chem 1995;270:23159-65.
190. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
191. Abrahamson JL, Lee JM, Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol 1995;15:6953-60.
192. Helin K, Lees JA, Vidai M, Dyson N, Harlow E, Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992;70:337-50.
193. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23.
194. Cress WD, Johnson DG, Nevins JR. A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. Mol Cell Biol 1993;13:6314-25.
195. Kaelin WG Jr, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 1992;70:351-64.
196. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, et al. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 1995;15:6864-74.
197. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase [published erratum appears in Proc Natl Sci U S A 1995;92:5249]. Proc Natl Acad Sci U S A 1995;92:2563-7.
198. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
199. Oliner JD, Kinzler KW, Meltzer PS, George DL. Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas [see comment citations in Medline]. Nature 1992;358:80-3.
200. Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T, Kaminski A, et al. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 1995;9:1288-96.
201. Cohen JS, Hogan ME. The new genetic medicines. Sci Am 1994;271:76-82.
202. Fox KR, Polucci P, Jenkins TC, Neidle S. A molecular anchor for stabilizing triple-helical DNA. Proc Natl Acad Sci U S A 1995;92:7887-91.
203. Mercola D, Cohen JS. Antisense approaches to cancer gene therapy. Cancer Gene Ther 1995;2:47-59.
204. Abarzua P, LoSardo JE, Gubler ML, Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 1995;55:3490-4.
205. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995;11. 933-9.
206. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83:237-45.
207. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995;11:763-70.
208. Milner J. DNA damage, p53 and anticancer therapies. Nat Med 1995; 1:879-80.
209. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996;334:316-8.
210. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
211. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
212. Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. FASEB J 1992;6:2450-5.
213. Krammer PH, Debatin KM. When apoptosis fails. Autoimmunily 1992;2:383-5.
214. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
215. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1-15.
216. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
217. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995;55:2507-10.
218. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Gonzalez-Garcia M, et al. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci U S A 1995;92:11024-8.
219. Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, Gonzalez-Garcia M, et al. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene 1994;9:2217-26.
220. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995; 9:600-11.
221. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
222. Rowan S, Ludwig RL, Haupt Y, Bates S, Lux X, Oren M, et al. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J 1996;15:827-38.
223. Robertson M. Antigen processing. Proteasomes in the pathway [news; see comment citations in Medline]. Nature 1991;353:300-1.
224. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilin N, et al. Characterization of peptides bound to the class 1 MHC molecule HLA-A2.1 by mass spectrometry [see comment citations in Medline]. Science 1992;255:1261-3.
225. Van Den Eynde B, Brichard VJ. New tumor antigens recognized by T cells. Curr Biol 1995;7:674-81.
226. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cellular Immunol In press.
227. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cellular Immunol. In press.
228. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res 1994;54:1175-7.
229. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al. Therapy of murine tumors with p53 wild type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
230. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 1995;92:11993-7.
231. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996;93:4781-6.
232. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-61.
233. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6:395-405.
234. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
235. Liu TJ, el-Naggar AK, McDonnell TJ, Stick KD, Wang M, Taylor DL, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995;55:3117-22.
236. Kiehntopf M, Brach MA, Hernnann F. Gene therapy in oncology - outlook, benefits and risks. Onkologie 1995;1(18 Suppl):16-26.
237. Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proc Natl Acad Sci U S A 1996; 93:4192-6.
238. Ettinghausen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv Surg 1995;28:223-54.
239. Milligan JF, Jones RJ, Froehler BC, Matteucci MD. Development of antisense therapeutics. Implications for cancer gene therapy. Ann N Y Acad Sci 1994;716:228-41.
240. Mullen CA, Blaese RM. Gene therapy of cancer. Cancer Chemother Biol Response Modif 1994;15:176-89.
241. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
242. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
243. Ritke MK, Rusnak JM, Lazo JS, Allan WP, Dive C, Heer S, et al. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol 1994;46:605-11.
244. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993;53:1853-61.
245. Benveniste P, Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci USA 1995;92:8373-7.
246. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 [see comment citation in Medline]. Cell 1994;79:329-39.
247. Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 1995;55:3712-5.
248. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DK, et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995;55:3706-11.
249. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994;54:6348-52.
250. Saito Y, Ogawa K. Wild type p53 and c-myc co-operation in generating apoptosis of a rat hepatocellular carcinoma cell line (FAA-HTC1). Oncogene 1995;11:1013-8.
251. Sabbatini P, Chiou SK, Rao L, White E. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 1995;15:1060-70.
252. Teodoro JG, Shore GC, Branton PE. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene 1995;11:467-74.
253. Sabbatini P, Lin J, Levine AJ, White E. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 1995;9:2184-92.
254. Lin HJ, Eviner V, Prendergast GC, White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol Cell Biol 1995;15:4536-44.
255. Bennett MR, Evan GI, Schwartz SM. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circ Res 1995;77:266-73.
256. Subramanian T, Tarodi B, Chinnadurai G. p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. Cell Growth Differ 1995;6:131-7.
257. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A 1994;91:3602-6.
258. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994;91:10918-22.
259. Chen CY, Faller DV. Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 1995;11:1487-98.
260. Wang HG, Millan JA, Cox AD, Der CJ, Rapp UR, Beck T, et al. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol 1995;129:1103-14.
261. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, et al. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1995;10:1269-74.
262. Faibairn LJ, Cowling GJ, Reipert BM, Dexter TM. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell 1993;74:823-32.
263. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995;55:2262-5.
264. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-74.
265. Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 1993;73:295-307.
266. Garcia I, Martinou I, Tsujimoto Y, Martinou JC. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 1992;258:302-4.
267. Davies AM, Rosenthal A. Neurons from mouse embryos with a null mutation in the tumour suppressor gene p53 undergo normal cell death in the absence of neurotrophins. Neurosci Lett 1994;182:112-4.
268. Martinou I, Fernandez PA, Missotten M, White E, Allet B, Sadone R, et al. Viral proteins E1B19K and p35 protect sympathetic neurons from cell death induced by NGF deprivation. J Cell Biol 1995;128:201-8.
269. Myers DE, Jun X, Waddick KG, Forsyth C, Cheestrom LM, Gunther RL, et al. Membrane-asociated CD19-LYN complex is an endogenous p53-independent and Bcl-2-independent regulator of apoptosis in human Blineage lymphoma cells. Proc Natl Acad Sci U S A 1995;92:9575-9.
270. Noguchi K, Nakajima M, Naito M, Tsuruo T. Inhibition by differentiation-inducing agents of wild-type p53-dependent apoptosis in HL-60 cells. Jpn J Cancer Res 1995;86:217-23.
271. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, et al. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 1995;87:1394-9.
272. Knox KA, Finney M, Milner AE, Gregory CD, Wakelam MJ, Michell RH, et al. Second-messenger pathways involved in the regulation of survival in germinal-centre B cells and in Burkitt lymphoma lines, Int J Cancer 1992;52:959-66.
273. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995;10:2297-305.
274. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995;95:2633-43.
275. Terada T, Nakanuma Y. Detection of apoptosis and expression of apoptosis-related proteins during human intrahepatic bile duct development. Am J Pathol 1995;146:67-74.
276. Chiou SK, Tseng CC, Rao L, White E. Functional complementation of the adenovirus E1B 19-kilodalton protein with Bcl-2 in the inhibition of apoptosis in infected cells. J Virol 1994;68:6553-66.
277. Beidler DR, Tewari M, Friesen PD, Poirier G, Dixit VM. The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis, J Biol Chem 1995;270:16526-8.
278. Talley AK, Dewhurst S, Perry SW, Douard SG, Gummulurru S, Fine SM, et al. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol 1995;15:2359-66.
279. Pulendran B, Kannourakis G, Nouri S, Smith KG, Nossal GJ. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells [see comment citation in Medline]. Nature 1995;375:331-4.
280. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 1995;85:359-67.
281. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995;11:493-504.
282. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 1995; 55:944-8.
283. Bies J, Wolff L. Acceleration of apoptosis in transforming growth factor beta 1-treated M1 cells ectopically expressing B-myb. Cancer Res 1995; 55:501-4.
284. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor beta 1. Cancer Res 1992;52:385-8.
285. Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 1994;72:455-62.
286. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
287. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
288. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrisco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.